19 AUG 2009
Signing of order on 1st July 2009
at the Hisun headquarters
GEA Lyophil, part of GEA Pharma Systems, has won a milestone order from the Zhejiang Hisun Pharmaceutical Co. Ltd. in Taizhou Zhejiang, China for the supply of pharmaceutical freeze dryers with automatic load and unload systems (ALUS®). The order is a major breakthrough in the region allowing Hisun to expand its operations into formulated pharmaceutical products for injection focus in oncology and infective diseases.
The order was signed on 1st July 2009 at the Hisun headquarters. GEA Lyophil GmbH will supply seven freeze drying systems and five ALUS systems with a total value in excess of 15 million euro. The equipment will be used at the new facilities in the Fuyang pharmaceutical valley and will allow Hisun to focus on the production of anti-tumour, anti-infective, general biologics and anti-TB product for both the domestic and export markets. Hisun is planning to invest over 100 million euro in the Fuyang facility making it one of the biggest pharmaceutical production sites in China.
GEA Lyophil is the technology leader for pharmaceutical freeze drying and ALUS® systems; this new order will help cement its leading role in China in the future. GEA Pharma Systems already holds an established position in China with a major manufacturing facility in Shanghai and an engineering, service and after-sales structure throughout the country.
GEA Lyophil won the Hisun contract because of its technical excellence, reputation for operational reliability and proven capability of running large engineering projects for the pharmaceutical industry.
Hisun has been a leading pharmaceutical manufacturer in China for over 50 years specialising in the production of APIs for antibiotics and oncology products. Its products include anti-infection, anti-parasite, endocrine regulation, immunosuppressant and antidepressant drugs. The company is one of the biggest players in China: home to one of the world’s fastest-growing pharmaceutical industries. Hisun exports more than 80% of its products and holds a leading market position in over 30 countries in the Far East, Europe and the USA.
The Chinese pharmaceutical industry is investing heavily in top quality production technology both for domestic and export pharmaceuticals. This recent order for GEA Lyophil is a clear illustration of this trend.
All business enquiries to:
Hubert Kluetsch
Director Sales & Marketing
GEA Lyophil GmbH
Tel: +49 (0) 2233/6999-220 Fax: +49 (0) 2233/6999-8220
Email: Hubert.Kluetsch@geagroup.com
For further editorial information contact:
Sharon Lyons
GEA Pharma Systems
Tel: +32 3 350 12 41
Email: sharon.lyons@geagroup.com